DDInter1729 DDInter1269
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
Sulindac {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Nateglinide
Sulindac {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Nateglinide
Sulindac {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Nateglinide
Sulindac {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Sulindac {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Aspartame
Aspartame {u} (Compound) resembles {v} (Compound) Nateglinide
Sulindac {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amphetamine
Amphetamine {u} (Compound) resembles {v} (Compound) Nateglinide
Sulindac {u} (Compound) causes {v} (Side Effect) Jaundice
Jaundice {u} (Side Effect) is caused by {v} (Compound) Ramipril
Ramipril {u} (Compound) resembles {v} (Compound) Nateglinide
Sulindac {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) interacts with {v} (Gene) ORM1
ORM1 {u} (Gene) is bound by {v} (Compound) Nateglinide
Sulindac {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Sulfasalazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Sulindac {u} (Compound) causes {v} (Side Effect) Jaundice
Jaundice {u} (Side Effect) is caused by {v} (Compound) Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Sulindac (Compound) binds ALB (Gene) and ALB (Gene) is bound by Nateglinide (Compound)
Sulindac (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Sulindac (Compound) binds ALB (Gene) and ALB (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Nateglinide (Compound)
Sulindac (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Sulindac (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Aspartame (Compound) and Aspartame (Compound) resembles Nateglinide (Compound)
Sulindac (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amphetamine (Compound) and Amphetamine (Compound) resembles Nateglinide (Compound)
Sulindac (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Ramipril (Compound) and Ramipril (Compound) resembles Nateglinide (Compound)
Sulindac (Compound) binds ALB (Gene) and ALB (Gene) interacts with ORM1 (Gene) and ORM1 (Gene) is bound by Nateglinide (Compound)
Sulindac (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Sulfasalazine (Compound) and Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Sulindac (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide